Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Account Payables

Last Annual Value

841.00K

3-Year CAGR

-32%

5-Year CAGR

-39%

10-Year CAGR

11%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Account Payables

CGEM · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
841.00K
-30.4%-23.3%N/A 
69.90M
2.6%3.5%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
2.84M
57.1%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
9.20M
6.6%21.3%N/A
5.41M
-16.3%-12.6%3.1%
3.38M
115.6%15.6%N/A
1.27M
-37.3%-8.6%N/A
4.76M
-14.8%-18.7%6.6%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21